This company has been marked as potentially delisted and may not be actively trading. resTORbio (TORC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock TORC vs. TELO, ATOS, SLN, MGNX, VERU, AVTE, VTYX, IMAB, CNTX, and ANLShould you be buying resTORbio stock or one of its competitors? The main competitors of resTORbio include Telomir Pharmaceuticals (TELO), Atossa Therapeutics (ATOS), Silence Therapeutics (SLN), MacroGenics (MGNX), Veru (VERU), Aerovate Therapeutics (AVTE), Ventyx Biosciences (VTYX), I-Mab (IMAB), Context Therapeutics (CNTX), and Adlai Nortye (ANL). These companies are all part of the "medical" sector. resTORbio vs. Telomir Pharmaceuticals Atossa Therapeutics Silence Therapeutics MacroGenics Veru Aerovate Therapeutics Ventyx Biosciences I-Mab Context Therapeutics Adlai Nortye resTORbio (NASDAQ:TORC) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, community ranking, analyst recommendations, earnings, risk, profitability and media sentiment. Is TORC or TELO more profitable? resTORbio's return on equity of -78.12% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets resTORbioN/A -78.12% -71.63% Telomir Pharmaceuticals N/A -1,170.58%-832.67% Do analysts rate TORC or TELO? Telomir Pharmaceuticals has a consensus price target of $15.00, indicating a potential upside of 504.84%. Given Telomir Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Telomir Pharmaceuticals is more favorable than resTORbio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score resTORbio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do institutionals & insiders hold more shares of TORC or TELO? 46.2% of resTORbio shares are owned by institutional investors. 11.8% of resTORbio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has stronger earnings & valuation, TORC or TELO? Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than resTORbio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioresTORbioN/AN/A-$82.74M-$2.41-0.22Telomir PharmaceuticalsN/AN/A-$16.53M-$0.58-4.28 Does the MarketBeat Community prefer TORC or TELO? resTORbio received 139 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Telomir Pharmaceuticals an outperform vote while only 67.14% of users gave resTORbio an outperform vote. CompanyUnderperformOutperformresTORbioOutperform Votes14167.14% Underperform Votes6932.86% Telomir PharmaceuticalsOutperform Votes2100.00% Underperform VotesNo Votes Does the media prefer TORC or TELO? In the previous week, resTORbio's average media sentiment score of 0.00 equaled Telomir Pharmaceuticals'average media sentiment score. Company Overall Sentiment resTORbio Neutral Telomir Pharmaceuticals Neutral Which has more volatility & risk, TORC or TELO? resTORbio has a beta of 2.43, meaning that its stock price is 143% more volatile than the S&P 500. Comparatively, Telomir Pharmaceuticals has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. SummaryresTORbio and Telomir Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks. Get resTORbio News Delivered to You Automatically Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TORC vs. The Competition Export to ExcelMetricresTORbioPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.17M$6.46B$5.31B$7.35BDividend YieldN/A3.20%5.45%4.29%P/E Ratio-0.296.9521.9417.82Price / SalesN/A231.03380.9597.68Price / CashN/A65.6738.2634.64Price / Book0.235.936.453.98Net Income-$82.74M$143.22M$3.22B$247.81M resTORbio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TORCresTORbioN/A$0.53-8.0%N/A-74.0%$19.17MN/A-0.29N/ATELOTelomir Pharmaceuticals1.3839 of 5 stars$2.74+1.9%$15.00+447.4%-68.8%$81.55MN/A-4.721ATOSAtossa Therapeutics1.8199 of 5 stars$0.63-2.5%$7.00+1,011.1%-56.1%$81.38MN/A-2.868Negative NewsSLNSilence Therapeutics2 of 5 stars$2.71+5.4%$40.67+1,400.6%-85.7%$81.11M$43.26M-1.73100News CoveragePositive NewsGap UpMGNXMacroGenics3.7513 of 5 stars$1.27-1.6%$7.38+480.7%-92.2%$80.12M$148.34M-0.80430News CoveragePositive NewsVERUVeru1.4433 of 5 stars$0.55+0.5%$4.33+694.5%-62.4%$79.84M$16.89M-2.10230AVTEAerovate Therapeutics0.8027 of 5 stars$2.71+1.9%$2.25-17.0%-87.3%$78.55MN/A-0.9120Gap UpVTYXVentyx Biosciences1.4571 of 5 stars$1.10+13.6%$10.00+809.1%-75.4%$78.24MN/A-0.4730IMABI-Mab3.1002 of 5 stars$0.96+42.8%$5.50+475.5%-52.8%$77.89M$3.27M0.00380Short Interest ↓Gap UpHigh Trading VolumeCNTXContext Therapeutics1.6643 of 5 stars$0.85+9.6%$6.17+621.4%-38.5%$76.68MN/A-0.947ANLAdlai Nortye1.5891 of 5 stars$2.08+7.0%$9.00+333.7%-83.9%$76.57M$5M0.00127Upcoming EarningsShort Interest ↑News Coverage Related Companies and Tools Related Companies Telomir Pharmaceuticals Alternatives Atossa Therapeutics Alternatives Silence Therapeutics Alternatives MacroGenics Alternatives Veru Alternatives Aerovate Therapeutics Alternatives Ventyx Biosciences Alternatives I-Mab Alternatives Context Therapeutics Alternatives Adlai Nortye Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TORC) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding resTORbio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share resTORbio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TORC Stock Free TORC Stock Alerts